Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association Between MDM2 SNP309 T>G and Risk of Gastric Cancer: A Meta-analysis

  • Tian, Xin (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University) ;
  • Tian, Ye (Department of Thoracic Surgery, the Fouth Affiliated Hospital of China Medical University) ;
  • Ma, Ping (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University) ;
  • Sui, Cheng-Guang (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University) ;
  • Meng, Fan-Dong (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University) ;
  • Li, Yan (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University) ;
  • Fu, Li-Ye (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University) ;
  • Jiang, Tao (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University) ;
  • Wang, Yang (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University) ;
  • Ji, Fu-Jian (Department of General Surgery, Second Hospital of Jilin University (Disease Treatment Center of Jilin University General Surgery)) ;
  • Fang, Xue-Dong (Department of General Surgery, Second Hospital of Jilin University (Disease Treatment Center of Jilin University General Surgery)) ;
  • Jiang, You-Hong (Molecular Oncology Department of Cancer Research Institute, the First Affiliated Hospital, China Medical University)
  • Published : 2013.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: As a negative regulator of P53, MDM2 plays an important role in carcinogenesis; a polymorphism in its promoter region. SNP309 T>G, is known to increase the expression of MDM2, thus being considered related to higher susceptibility to neoplasia. However, no agreement has been achieved regarding its effects on gastric cancer. Methods: The present systematic meta-analysis was performed based on comprehensive literature search from Pubmed, Web of science and CBM databases. Results: It was suggested from 6 independent studies that the GG genotype is associated with a significantly increased risk of gastric cancer (Recessive: OR = 1.43, 95% CI = 1.08-1.91, P = 0.013), and subgroup analysis also confirmed the relationship (English publications-recessive model: OR = 1.45, 95% CI = 1.10-1.91, P = 0.009; Studies in China-recessive model: OR = 1.58, 95% CI = 1.08-2.30, P = 0.017). No publication bias was detected. Conclusion: The meta-analysis indicated a significant inverse association between GG genotype carriage and elevated risk of gastric cancer. However, more studies and detailed information are needed to fully address the topic.

Keywords

References

  1. Bond GL, Hu W, Bond EE, et al (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602. https://doi.org/10.1016/j.cell.2004.11.022
  2. Bond GL, Hu W, Levine A (2005). A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res, 65, 5481-4. https://doi.org/10.1158/0008-5472.CAN-05-0825
  3. Cai X, Yang M (2012). The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis. J Cancer Res Clin Oncol, 138, 555-61. https://doi.org/10.1007/s00432-011-1124-8
  4. Chen T, Yi SH, Liu XY, et al (2012). Meta-analysis of associations between the MDM2-T309G polymorphism and prostate cancer risk. Asian Pac J Cancer Prev, 13, 4327-30. https://doi.org/10.7314/APJCP.2012.13.9.4327
  5. Cho YG, Choi BJ, Song JH, et al (2008). No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients. Neoplasma, 55, 256-60.
  6. Crew KD, Neugut AI (2006). Epidemiology of gastric cancer. World J Gastroenterol, 12, 354-62.
  7. Eischen CM, Lozano G (2009). p53 and MDM2: antagonists or partners in crime? Cancer Cell, 15, 161-2. https://doi.org/10.1016/j.ccr.2009.02.004
  8. Er LM, Niu WW, Xu ZB, et al (2009). Relation of MDM2 gene polymorphism and Helicobacter pylori infection to gastric cardiac carcinoma. Clin Focus, 24, 1594-7.
  9. Er LM (2012). Relevance of MDM2 polymorphisms with esophageal squamous cell carcinoma, gastric adenocarcinoma and double primary cancers in esophagus and stomach. Modern Prev Med, 39, 3342-4.
  10. Gajjar M, Candeias MM, Malbert-Colas L, et al (2012). The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell, 21, 25-35. https://doi.org/10.1016/j.ccr.2011.11.016
  11. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  12. Jemal A, Center MM, DeSantis C, et al (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-907. https://doi.org/10.1158/1055-9965.EPI-10-0437
  13. Knappskog S, Bjornslett M, Myklebust LM, et al (2011). The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell, 19, 273-82. https://doi.org/10.1016/j.ccr.2010.12.019
  14. Knappskog S, Lonning PE (2011). Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription, 2, 207-10. https://doi.org/10.4161/trns.2.5.16813
  15. Li YQ, et al (2010). Interaction of Helicobacter pylori with MDM2 SNP309 polymorphisms and susceptibility to gastric cancer studies. Nanjing Medical School.
  16. Liu J, Zheng Y, Lei D, et al (2011). MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis. Asian Pac J Cancer Prev, 12, 1899-903.
  17. Ma HB, Huang T, Han F, et al (2012). Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis. Asian Pac J Cancer Prev, 13, 2841-6. https://doi.org/10.7314/APJCP.2012.13.6.2841
  18. Ohmiya N, Taguchi A, Mabuchi N, et al (2006). MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol, 24, 4434-40. https://doi.org/10.1200/JCO.2005.04.1459
  19. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  20. Society AC (2013). Cancer Facts & Figures 2013. Atlanta: American Cancer Society.
  21. Stolte M, Meining A (1998) Helicobacter pylori and Gastric Cancer. Oncologist, 3, 124-8.
  22. Stommel JM, Wahl GM (2005). A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle, 4, 411-7. https://doi.org/10.4161/cc.4.3.1522
  23. Wang X, Yang J, et al (2009). Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter, is associated with gastric cancer susceptibility in Chinese patients. Helicobacter, 14, 114-9.
  24. Yang L (2006). Incidence and mortality of gastric cancer in China. World J Gastroenterol, 12, 17-20.
  25. Yang M, Guo Y, Zhang X, et al (2007). Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis, 28, 1996-2001. https://doi.org/10.1093/carcin/bgm168
  26. Zhang L, et al (2011). Association of gene polymorphisms with Helicobacter pylori related gastric cancer in a Chinese population. Chongqing Medical School.
  27. Zhao P, Dai M, Chen W, et al (2010). Cancer trends in China. Jpn J Clin Oncol, 40, 281-5. https://doi.org/10.1093/jjco/hyp187

Cited by

  1. Lack of Association between Bax Promoter (-248G>A) Single Nucleotide Polymorphism and Susceptibility towards Cancer: Evidence from a Meta-Analysis vol.8, pp.10, 2013, https://doi.org/10.1371/journal.pone.0077534
  2. The MDM2 SNP309T>G Polymorphism Increases Bladder Cancer Risk among Caucasians: a Meta-analysis vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5277
  3. Effects of p53 Codon 72 and MDM2 SNP309 Polymorphisms on Gastric Cancer Risk among the Iranian Population vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7413
  4. Quantitative assessment of the associations between DNA repair gene XRCC3 Thr241Met polymorphism and gastric cancer vol.35, pp.2, 2014, https://doi.org/10.1007/s13277-013-1219-8
  5. promoter polymorphisms and uterine leiomyoma in South-East Iran: A preliminary report vol.41, pp.5, 2014, https://doi.org/10.1111/jog.12625
  6. Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3759
  7. Role of E3 ubiquitin ligases in gastric cancer vol.21, pp.3, 2015, https://doi.org/10.3748/wjg.v21.i3.786
  8. Association of THBS1 rs1478605 T>C in 5′-untranslated regions with the development and progression of gastric cancer vol.3, pp.2, 2015, https://doi.org/10.3892/br.2015.414
  9. Genetic association of single nucleotide polymorphisms in P53 pathway with gastric cancer risk in a Chinese Han population vol.32, pp.1, 2015, https://doi.org/10.1007/s12032-014-0401-1
  10. Investigation of the association between the MDM2 T309G polymorphism and gastric cancer vol.7, pp.5, 2017, https://doi.org/10.3892/br.2017.978